https://scholars.lib.ntu.edu.tw/handle/123456789/564884
標題: | Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells | 作者: | Pan S.-L. JIH-HWA GUH Huang Y.-W. Chern J.-W. Chou J.-Y. Teng C.-M. |
公開日期: | 2003 | 卷: | 169 | 期: | 2 | 起(迄)頁: | 724-729 | 來源出版物: | Journal of Urology | 摘要: | Purpose: It has been suggested that terazosin has an inhibitory effect on prostate tumor growth. We determined if terazosin action contributes to direct suppression of the angiogenic effect. Materials and Methods: PC-3 cells and primary cultures of human benign prostatic cells were used in this study. The cytotoxic effect was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and lactate dehydrogenase release reaction. The in vivo angiogenic effect was determined in nude mice models, followed by histological examination and quantification by the hemoglobin detection assay. In vitro determination of cell migration, proliferation and tube formation was performed in cultured human umbilical vein endothelial cells. Results: Terazosin induced cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 μM. The positive terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling and lactate dehydrogenase release reaction was associated with terazosin induced cytotoxicity, indicating apoptotic and necrotic cell death. Furthermore, cytotoxicity due to terazosin action was not a common characteristic of a quinazoline based structure. Terazosin significantly inhibited vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 μM., showing that it had a more potent anti-angiogenic than cytotoxic effect. Terazosin also effectively inhibited vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 μM., respectively). Conclusions: Together our data suggest that terazosin shows direct anti-angiogenic activity through the inhibition of proliferation and tube formation in endothelial cells. This action may partly explain the in vivo antitumor potential of terazosin. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037304344&doi=10.1016%2fS0022-5347%2805%2964002-5&partnerID=40&md5=d69c36b5b66a554cd14c540bee973fb2 https://scholars.lib.ntu.edu.tw/handle/123456789/564884 |
ISSN: | 225347 | DOI: | 10.1016/S0022-5347(05)64002-5 | SDG/關鍵字: | 2 [4 [4 (2 methoxyphenyl)piperazinyl]butyl]amino 4 cyclohexylaminoquinazolin; 4 [3 [4 (2 methoxyphenyl)piperazinyl]propyl]aminoquinazolin 2 carboxamide; alpha 1 adrenergic receptor blocking agent; angiogenesis inhibitor; ethyl 4 [3 [4 (2 methoxyphenyl)piperazinyl]aminoquinazolin 2 carboxylate]; ew 154; ew 65; fh 71; lactate dehydrogenase; quinazoline derivative; terazosin; thymidine; tritium; unclassified drug; vasculotropin; angiogenesis; animal model; apoptosis; article; cancer cell; cell migration; controlled study; drug cytotoxicity; drug structure; endothelium cell; human; human cell; male; mouse; nonhuman; nude mouse; priority journal; prostate adenocarcinoma; prostate carcinoma |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。